ARS Pharmaceuticals (SPRY) Total Current Liabilities (2020 - 2026)

ARS Pharmaceuticals has reported Total Current Liabilities for 7 years, with the latest figure at $49.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 79.61% year-over-year to $49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.6 million (up 79.61% YoY) and the FY2025 annual result came in at $39.1 million, up 67.0% from the prior year.
• Total Current Liabilities improved to $49.6 million in Q1 2026 per SPRY's latest filing, from $39.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $50.9 million in Q3 2025 and troughed at $2.4 million in Q4 2023.
• A 5-year average of $19.5 million and a median of $11.2 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities sank 74.0% in 2022, then jumped 880.34% in 2024.
• Over 5 years, Total Current Liabilities stood at $5.4 million in 2022, then plunged by 56.08% to $2.4 million in 2023, then surged by 880.34% to $23.4 million in 2024, then soared by 67.0% to $39.1 million in 2025, then grew by 26.74% to $49.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $49.6 million, $39.1 million, and $50.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.